Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Sanofi plans to operate its Consumer Healthcare unit as a standalone business in a move which is being viewed as a prelude to a potential spin-off.
The French pharma giant’s CEO Paul Hudson – who took the reins in September – outlined his ambition to shake-up Consumer Healthcare before revealing more detailed strategic plans during Sanofi’s Capital Markets Day
UK-based Venture Life is divesting its CDMO business and some non-core products to focus its attention on growing its consumer health operation.
“The situation has evolved considerably” since Kenvue gave its initial full-year outlook in February, “and remains quite fluid,” says president and CEO Thibaut Mongon as firm reports Q1 net sales decreasing 3.9% to $3.7bn
Looming imposition of tariffs by Trump on imports from most every country had an influence on consumers during the January-March period, particularly on online shopping. Increasing product prices on the table, “but our efforts are going to start with cost savings,” says CFO Christine Sacco.
